Health Canada approves Taltz for pediatric patients with plaque psoriasis – Eli Lilly

Health Canada issued a Notice of Compliance for Taltz (ixekizumab), from Eli Lilly, injection, 80 mg/mL, for the treatment of pediatric patients from six to less than 18 years of age with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. About one million Canadians, including children, live with psoriasis.

The efficacy, safety, and tolerability of Taltz in patients ages six to less than 18 years of age was demonstrated in a randomized, double-blind, placebo-controlled Phase III study that included 171 patients with moderate- to severe plaque psoriasis. The co-primary endpoints of the study were the proportion of patients achieving at least 75 per cent improvement from baseline on their Psoriasis Area and Severity Index score (PASI 75) and a static Physician’s Global Assessment of clear or almost clear skin (sPGA 0,1) at Week 12.